Loading organizations...

Juvenescence is a technology company.
Juvenescence develops clinical-stage medicines extending healthy human lifespan by targeting core aging mechanisms for disease prevention and treatment. Its proprietary AI-enabled drug discovery platform integrates AI, machine learning, and a Biomedical Knowledge Graph to optimize novel small molecule, biologic, and cell therapies. This technical approach underpins its efforts to innovate within the longevity sector.
Jim Mellon and Greg Bailey founded Juvenescence in 2017. Their insight: addressing fundamental aging processes significantly improves human health. Mellon, an investor, and Bailey, with pharmaceutical development expertise, established the company to pioneer scientific disease prevention in longevity biotechnology, leveraging their combined experience.
The company targets individuals seeking to mitigate aging's impact and prevent chronic conditions. Juvenescence envisions transforming aging, ensuring extended lifespans include an enhanced quality of life. Focused on early intervention, it develops preventative medicines delivering therapeutic benefits for a healthier future, pursuing its long-term mission.
Juvenescence has raised $238.0M across 4 funding rounds.
Key people at Juvenescence.
Juvenescence has raised $238.0M in total across 4 funding rounds.
Key people at Juvenescence.
Juvenescence is a clinical-stage biotechnology company developing innovative medicines and therapies to extend healthy human lifespan by targeting core aging mechanisms, preventing age-related diseases, and promoting regeneration.[1][2][3] It builds a pipeline of AI-enabled therapeutics across small molecules, biologics, and cell therapies for areas like cognition, cardio-metabolism, immunity, and cellular repair, while maintaining strategic investments in portfolio companies focused on regenerative medicine, AI platforms, and nutritional interventions.[2][3][4] The company serves patients with age-related conditions and broader populations seeking preventive healthspan extension, addressing the problem of chronic disease burden through early intervention and longevity-focused innovation, with momentum including multiple clinical medicines entering Phase I or II trials by 2025 and recent acquisitions like AI drug discovery firm Ro5.[2][3]
Juvenescence was founded by Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan, serial entrepreneurs with a track record in major biopharma deals, including leading two of the decade's largest such as Biohaven's $11.6 billion sale to Pfizer.[3] The idea emerged from their expertise in drug development, synthetic biology, and longevity science, establishing the company in the Isle of Man (with British Virgin Islands ties) to pioneer therapies modifying aging processes.[1][5] Early traction built through assembling a world-class R&D team led by CEO Dr. Richard Marshall CBE, boasting over 150 years of combined pharmaceutical experience and approvals for drugs generating $30 billion in peak sales; pivotal moments include advancing a diverse pipeline and the 2025 acquisition of Ro5 to integrate AI drug discovery.[2][3]
Juvenescence rides the surging longevity biotech trend, fueled by advances in AI-driven drug discovery, multi-omics, and regenerative medicine amid a global aging population projected to double chronic disease burdens.[2][3] Timing aligns with regulatory shifts toward aging as a treatable condition and investor enthusiasm for healthspan tech, amplified by partnerships like M42 to build life sciences hubs in Abu Dhabi.[3] Market forces favoring it include plummeting AI computation costs, exponential growth in single-cell data, and demand for preventive therapies amid rising healthcare costs; the company influences the ecosystem by cross-pollinating its portfolio (e.g., LyGenesis' liver regeneration trials) and validating longevity as a viable sector through clinical milestones.[3][4]
Juvenescence is poised to lead AI-biotech convergence in longevity, with near-term catalysts like Phase I/II readouts and pipeline expansion potentially driving partnerships or exits akin to founders' past successes.[3] Trends like scalable cell therapies, patient-embedded multi-omics, and global healthspan investments will shape its path, evolving its influence from pipeline innovator to ecosystem orchestrator via Abu Dhabi hubs and portfolio synergies.[3][4] As aging therapies mature, Juvenescence could redefine healthy lifespan, turning its prevention vision into a multi-billion-dollar reality.
Juvenescence has raised $238.0M in total across 4 funding rounds.
Juvenescence's investors include M42, 305 Ventures, Khosla Ventures, Mike Cannon-Brookes, Michael Spencer, Foresite Capital, Ed Mathers, Venrock, Andrew R Banks, Karim Hakimzadeh, Christian Angermayer.
Juvenescence has raised $238.0M across 4 funding rounds. Most recently, it raised $76.0M Series B in May 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2023 | LyGenesis | $19.0M Series A | Justin Briggs | Aisling Capital, Frazier Healthcare Partners, RA Capital, Richard Marshall |
| Jan 1, 2023 | Morphoceuticals | $8.0M Seed | Amy Kruse | Satori Capital, Sunil Paul, Alexander Pickett |
| Oct 21, 2019 | LyGenesis | $4.0M Other Equity | Greg Bailey, Sergey Young | — |
| May 1, 2018 | LyGenesis | $3.0M Series A | Greg Bailey | Aisling Capital, Frazier Healthcare Partners, RA Capital |
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 26, 2025 | $76.0M Series B | M42 | |
| Aug 1, 2019 | $100.0M Series B | 305 Ventures, Khosla Ventures, Mike Cannon-Brookes, Michael Spencer | |
| Jun 11, 2018 | $50.0M Series A | ||
| Jan 1, 2018 | $12.0M Seed | Foresite Capital, Ed Mathers, Venrock, Andrew R Banks, Karim Hakimzadeh, Christian Angermayer |